标题
Long-acting slow effective release antiretroviral therapy
作者
关键词
-
出版物
Expert Opinion on Drug Delivery
Volume -, Issue -, Pages 1-11
出版商
Informa UK Limited
发表日期
2017-01-27
DOI
10.1080/17425247.2017.1288212
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs
- (2017) Divya Prakash Gnanadhas et al. JOURNAL OF CLINICAL INVESTIGATION
- Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS
- (2016) Madhavan Nair et al. ADVANCED DRUG DELIVERY REVIEWS
- Tracking development assistance for HIV/AIDS
- (2016) Matthew T. Schneider et al. AIDS
- Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
- (2016) Adrian S. Ray et al. ANTIVIRAL RESEARCH
- Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia
- (2016) Yvette N. Lamb et al. DRUGS
- Triple Activity of Lamivudine Releasing Sulfonated Polymers against HIV-1
- (2016) Maarten Danial et al. MOLECULAR PHARMACEUTICS
- Development and characterization of a long-acting nanoformulated abacavir prodrug
- (2016) Dhirender Singh et al. Nanomedicine
- Persistent HIV-1 replication maintains the tissue reservoir during therapy
- (2016) Ramon Lorenzo-Redondo et al. NATURE
- International AIDS Society global scientific strategy: towards an HIV cure 2016
- (2016) Steven G Deeks et al. NATURE MEDICINE
- Saquinavir Loaded Acetalated Dextran Microconfetti – a Long Acting Protease Inhibitor Injectable
- (2016) Michael A. Collier et al. PHARMACEUTICAL RESEARCH
- The promise and pitfalls of long-acting injectable agents for HIV prevention
- (2016) Raphael J. Landovitz et al. Current Opinion in HIV and AIDS
- Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
- (2016) Alison L. Hill et al. PLoS Pathogens
- Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment
- (2016) Ian McGowan et al. Lancet HIV
- Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing
- (2016) Rafal Kaminski et al. Scientific Reports
- Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure Duration as Well as Triple-Drug Combination Levels in Cells Within Lymph Nodes and Blood in Primates
- (2015) Jennifer P. Freeling et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice
- (2015) Pavan Puligujja et al. ANTIVIRAL RESEARCH
- Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations
- (2015) Pavan Puligujja et al. BIOMATERIALS
- Embracing failure: What the Phase III progesterone studies can teach about TBI clinical trials
- (2015) Donald G. Stein BRAIN INJURY
- Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs – Modern Trojan horses to combat HIV
- (2015) Lakshmi Narashimhan Ramana et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Sustained-release nanoART formulation for the treatment of neuroAIDS
- (2015) Rahul Jayant et al. International Journal of Nanomedicine
- Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice
- (2015) Luisa Fiandra et al. Nanomedicine-Nanotechnology Biology and Medicine
- Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages
- (2015) Mariluz Araínga et al. Retrovirology
- A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge
- (2015) Chasity D. Andrews et al. Science Translational Medicine
- Long-acting rilpivirine for HIV prevention
- (2015) Akil Jackson et al. Current Opinion in HIV and AIDS
- Cabotegravir long-acting for HIV-1 prevention
- (2015) Chasity D. Andrews et al. Current Opinion in HIV and AIDS
- Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission
- (2015) Martina Kovarova et al. PLoS Pathogens
- Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy
- (2015) M.S. Palombo et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings
- (2014) Marco Vitoria et al. ANTIVIRAL THERAPY
- A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis
- (2014) A G A Jackson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies
- (2014) Benson Edagwa et al. CURRENT MEDICINAL CHEMISTRY
- Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes
- (2014) Benson J. Edagwa et al. FASEB JOURNAL
- Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
- (2014) William Spreen et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Mental, Neurological, and Substance Use Disorders in People Living With HIV/AIDS in Low- and Middle-Income Countries
- (2014) Dixon Chibanda et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy
- (2013) Nagsen Gautam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia
- (2013) Eun Ji Park et al. ARCHIVES OF PHARMACAL RESEARCH
- Functionalizing Nanoparticles with Biological Molecules: Developing Chemistries that Facilitate Nanotechnology
- (2013) Kim E. Sapsford et al. CHEMICAL REVIEWS
- Common AIDS-associated opportunistic infections
- (2013) E. Ong CLINICAL MEDICINE
- Emerging strategies to deplete the HIV reservoir
- (2013) Nancie M. Archin et al. CURRENT OPINION IN INFECTIOUS DISEASES
- The New Small-Molecule Mixed-Lineage Kinase 3 Inhibitor URMC-099 Is Neuroprotective and Anti-Inflammatory in Models of Human Immunodeficiency Virus-Associated Neurocognitive Disorders
- (2013) D. F. Marker et al. JOURNAL OF NEUROSCIENCE
- Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients
- (2013) Qing Ma et al. JOURNAL OF NEUROVIROLOGY
- Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections
- (2013) Pavan Puligujja et al. Nanomedicine-Nanotechnology Biology and Medicine
- Long-acting injectable antiretrovirals for HIV treatment and prevention
- (2013) William R. Spreen et al. Current Opinion in HIV and AIDS
- Overcoming pharmacologic sanctuaries
- (2013) Theodore J. Cory et al. Current Opinion in HIV and AIDS
- Long-Acting Antipsychotic Medications
- (2012) Raman Baweja et al. CURRENT DRUG TARGETS
- Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana
- (2012) Michael C. Thigpen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
- (2012) Jared M. Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tuberculosis and HIV Co-Infection
- (2012) Andrzej Pawlowski et al. PLoS Pathogens
- Human Immunodeficiency Virus type 1 Endocytic Trafficking Through Macrophage Bridging Conduits Facilitates Spread of Infection
- (2011) Irena Kadiu et al. Journal of Neuroimmune Pharmacology
- Activity and Safety of Synthetic Lectins Based on Benzoboroxole-Functionalized Polymers for Inhibition of HIV Entry
- (2011) Alamelu Mahalingam et al. MOLECULAR PHARMACEUTICS
- Macrophage endocytic trafficking of antiretroviral nanoparticles
- (2011) Irena Kadiu et al. Nanomedicine
- Prodrugs--from Serendipity to Rational Design
- (2011) K. M. Huttunen et al. PHARMACOLOGICAL REVIEWS
- Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation
- (2010) G. van 't Klooster et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment‐Naive, HIV‐1–Infected Individuals Commencing cART? A Randomized, Controlled Study
- (2010) Alan Winston et al. CLINICAL INFECTIOUS DISEASES
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
- (2010) Robert M. Grant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women
- (2010) Q. Abdool Karim et al. SCIENCE
- Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance
- (2009) Christina M Marra et al. AIDS
- Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment
- (2009) Lieven Baert et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS
- (2009) H. Dou et al. JOURNAL OF IMMUNOLOGY
- NanoART synthesis, characterization, uptake, release and toxicology for human monocyte–macrophage drug delivery
- (2009) Ari S Nowacek et al. Nanomedicine
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
- (2009) Nicolas Chomont et al. NATURE MEDICINE
- The Challenge of Finding a Cure for HIV Infection
- (2009) D. D. Richman et al. SCIENCE
- Prodrugs: design and clinical applications
- (2008) Jarkko Rautio et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now